Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Glucagon-like peptide-1 receptor agonist：Semaglutide for Autism Spectrum Disorder

This study is a 6-month, two-arm, RCT which will measure the effectiveness and safety of semaglutide in adolescents aged 12-18 years with autism spectrum disorder (ASD) and obesity. The primary outcome is change in body mass index (body-mass index (BMI), kg/m²) from baseline to Month 6.

Official registry: https://clinicaltrials.gov/study/NCT07770152 · Children's Hospital Medical Center, Cincinnati · enrollment listed as 42

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Glucagon-like peptide-1 receptor agonist：Semaglutide, or Lifestyle Management (LSM) Counseling. The registry lists allocation as randomized. This study is a 6-month, two-arm, RCT which will measure the effectiveness and safety of semaglutide in adolescents aged 12-18 years with autism spectrum disorder (ASD) and obesity.

They plan to enroll about 42 people at Cincinnati. Taking part typically means taking a study drug (or dummy pill), following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Semaglutide for Metabolic and Adiposity-Related Targets in Youth With Autism Spectrum Disorder (SMART-ASD)

Interventions: Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling

Primary outcome (registry wording): Number of Participants With Percent Change in BMI (kg/m2)

Who it is for (from inclusion criteria)

  • Ages 12 Years to 18 Years
  • (Semaglutide Group):
  • Epic-confirmed diagnosis of ASD
  • Obesity defined as body-mass index (BMI) ≥95th percentile for age and sex
  • Have Medicaid or other insurance that will cover semaglutide or the parent is willing to pay for semaglutide out of pocket
  • Can attend in-person, e-visits, or telehealth visits for 12 months

Public study contact (from the registry)

Mary Banks

513-803-3123

mary.banks@cchmc.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07770152 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07770152?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07770152?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary